Platelet-type bleeding disorder 8

👪

Inheritance

1

Autosomal Recessive HP:0000007

Every genetically resolved patient in the cached literature is biallelic: three with homozygous frameshift variants causing premature truncation, and one compound heterozygote carrying p.Arg256Gln and p.Arg265Trp. A fourth patient carried one frameshift allele together with an apparently normal allele presumed silenced by a second, unidentified variant - consistent with recessive inheritance and an undetected second hit rather than with dominant disease, though it is explicitly unresolved in the source. Curated as autosomal recessive on that basis. Heterozygous carrier phenotype is not characterized in the cached sources, and a dominant-negative P2RY12 allele, though proposed in the wider literature, is not evidenced by anything cited here - so no dominant mode is asserted, and adding one would need its own citation and verified snippet.

Autosomal recessive inheritance

Show evidence (2 references)

PMID:15852220 SUPPORT Human Clinical

"Sequence analysis of the P2Y (12) locus of three of these patients revealed homozygous mutations that produced a frame shift mutation and premature truncation of the protein."

Establishes homozygous loss-of-function genotypes in the originally described severe-deficiency patients, the basis for the recessive assignment.

PMID:15852220 SUPPORT Human Clinical

"The fourth patient had an allele with a frame shift mutation and a normal allele, which could be silenced by an additional, as yet unknown, mutation."

PARTIAL - this patient's second allele was never identified, so the case is consistent with but does not independently establish recessive inheritance. Recorded because the ambiguity is a real caveat for diagnostic sequencing, not because it supports the assignment.

?

Discussions and Knowledge Gaps

1

Why is lifelong congenital P2Y12 loss only mildly to moderately haemorrhagic when acute pharmacological P2Y12 blockade measurably increases major bleeding?

KNOWLEDGE GAP gap_congenital_vs_pharmacological_p2y12_loss

Attached to

pathophysiology#Failure of Primary Hemostatic Plug Formation pathophysiology#Mild to Moderate Mucocutaneous Bleeding Diathesis

The same receptor is lost in both cases, yet the clinical weight differs. Patients with congenital defects are described as mildly to moderately affected, while the newer antagonists, which inhibit P2Y12 effectively in most patients, increase the incidence of major bleeding. Several explanations are possible and are not distinguished by the available evidence: lifelong developmental compensation absent in an acutely treated patient; the fact that treated patients are older, comorbid and usually also taking aspirin; ascertainment bias, since mildly affected congenital cases are the ones that come to attention; or a genuinely more complete blockade by drug than by the reported hypomorphic alleles. The question is not academic - it determines whether these patients can be counselled using the much larger evidence base from antiplatelet trials, which would otherwise be the obvious source of guidance for a disorder with only a handful of reported cases.

Proposed experiments

Matched comparison of residual P2Y12 function and bleeding phenotype

exp_p2y12_congenital_vs_treated_matched_comparison

Quantify residual ADP-induced adenylyl cyclase inhibition in congenital P2Y12-defect patients and in ticagrelor-treated volunteers, and pair each with a standardized bleeding-assessment tool score. If congenital patients retain more residual signalling than fully inhibited treated subjects, the difference is one of degree; if they do not, the explanation lies in compensation or comorbidity rather than in the receptor.

Show evidence (1 reference)

PMID:20966167 SUPPORT Human Clinical

"Although they increase the incidence of major bleedings, the net clinical benefit is in favor of the new P2Y₁₂ inhibitors."

Establishes the drug-side half of the discrepancy - effective blockade does increase major bleeding - against which the mild congenital phenotype stands to be explained.

⚙

Pathophysiology

5

Loss of Function in P2RY12

Variants in P2RY12 cause the disorder by two distinct routes, both documented. In the severe-deficiency families the alleles are frameshifts with premature truncation of the protein, so no receptor reaches the surface. In at least one compound heterozygote the receptor is expressed and trafficked normally but is dysfunctional: p.Arg256Gln in transmembrane helix 6 and p.Arg265Trp in extracellular loop 3 both reach the cell surface in transfected cells and both fail to transduce properly, which identifies that region as structurally and functionally critical. A quantitative assay of receptor expression would therefore miss the second class entirely.

platelet CL:0000233

Genetic context variant_origin: GERMLINE functional_impact_category: LOSS_OF_FUNCTION

Downstream

Loss of Gi-Coupled ADP Signalling Whether absent or non-functional, the receptor no longer transduces the ADP signal.

Show evidence (2 references)

PMID:15852220 SUPPORT Human Clinical

"Sequence analysis of the P2Y (12) locus of three of these patients revealed homozygous mutations that produced a frame shift mutation and premature truncation of the protein."

Documents the null allele class in the originally described severe-deficiency patients.

PMID:15852220 SUPPORT In Vitro

"Neither mutation blocked the ability of the P2Y (12) receptor to translocate to the CHO cell surface."

Establishes the dysfunctional-but-expressed allele class, which is why this node distinguishes the two routes.

Loss of Gi-Coupled ADP Signalling

The rate-limiting lesion. P2Y12 is negatively coupled to adenylyl cyclase through Gi, and the functional test that confirms the diagnosis is exactly this step: in cells expressing wild-type receptor, ADP strongly inhibits the forskolin-induced rise in cyclic AMP across the full concentration range, whereas the mutant receptors are only partially inhibitory. Because cyclic AMP restrains platelet activation, failure to lower it leaves the platelet partially braked at the moment it should be committing to aggregation.

platelet CL:0000233

adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 ↓ DECREASED

P2Y12 ADP receptor activity GO:0001621 ⇓ LOSS OF FUNCTION

Downstream

Loss of Sustained Aggregation and Agonist-Induced Secretion Potentiation The Gi arm is what sustains aggregation and potentiates secretion.

Show evidence (2 references)

PMID:15852220 SUPPORT Human Clinical

"The other ADP receptor, P2Y (12), is negatively coupled to adenylyl cyclase through Gi and mediates a progressive and sustained ADP-induced aggregation not preceded by shape change."

States the receptor's coupling and the specific aggregation component it mediates, which is what this node records as lost.

PMID:15852220 SUPPORT In Vitro

"ADP at all tested concentrations (0.1 to 10 muM) greatly inhibited the forskolin-induced increase of cyclic adenosine monophosphate (cAMP) in CHO cells transfected with wild-type P2Y (12), whereas CHO cells transfected with either mutant protein were only partially inhibited by ADP."

The heterologous assay establishing the signalling defect at the adenylyl cyclase step described here.

Loss of Sustained Aggregation and Agonist-Induced Secretion Potentiation

The functional consequence has two parts, and the second is easy to overlook. The obvious one is that the sustained, irreversible phase of ADP aggregation is lost while the P2Y1-dependent shape change and initial reversible wave remain, so aggregation to ADP is incomplete and reverses even at high agonist concentrations - the diagnostic signature. The less obvious one is that P2Y12 also potentiates secretion induced by several other agonists, so the defect degrades the amplification loop generally rather than only the response to ADP.

platelet CL:0000233

platelet aggregation GO:0070527 ↓ DECREASED platelet degranulation GO:0002576 ↓ DECREASED

Downstream

Failure of Primary Hemostatic Plug Formation Loss of sustained aggregation and secretory amplification leaves the plug unstable.

Show evidence (2 references)

PMID:15852220 SUPPORT Human Clinical

"In addition, this receptor plays an important role in the potentiation of platelet secretion induced by several platelet agonists. The combined action of P2Y (1) and P2Y (12) is necessary for the full platelet aggregation response to ADP."

Supports both halves of this node - the secretion-potentiation role and the requirement for both receptors for a full ADP response.

PMID:20966167 SUPPORT Human Clinical

"Defects of P2Y₁₂ should be suspected when ADP, even at high concentrations (≥ 10 μM), is unable to induce full, irreversible platelet aggregation."

States the diagnostic aggregation signature that this node's first half describes.

Failure of Primary Hemostatic Plug Formation

A partial rather than a total failure, which is why the bleeding is milder than in the receptor and integrin disorders: adhesion, shape change, the initial aggregation wave and the integrin itself are all intact, and what is lost is the amplification that consolidates the plug. The clearest evidence that this step matters haemostatically is pharmacological - blocking the same receptor in healthy people is potently antithrombotic and does increase major bleeding.

primary hemostasis GO:0007599 ↓ DECREASED

Downstream

Mild to Moderate Mucocutaneous Bleeding Diathesis Failure of platelet-dependent primary hemostasis.

Show evidence (1 reference)

PMID:20966167 SUPPORT Human Clinical

"Drugs that inhibit P2Y₁₂ are potent antithrombotic drugs, attesting the central role played by P2Y₁₂ in platelet thrombus formation."

Pharmacological evidence that this receptor's contribution to platelet thrombus formation is haemostatically consequential.

Mild to Moderate Mucocutaneous Bleeding Diathesis

Mucocutaneous bleeding with excessive post-surgical and post-traumatic blood loss - the same site pattern as the rest of the family but at the mild end of its severity range, so the disorder is characteristically unmasked by a haemostatic challenge rather than presenting spontaneously.

primary hemostasis GO:0007599 ↓ DECREASED

Show evidence (1 reference)

PMID:20966167 SUPPORT Human Clinical

"Patients with congenital P2Y₁₂ defects display a mild to moderate bleeding diathesis, characterized by mucocutaneous bleedings and excessive post-surgical and post-traumatic blood loss."

States the severity band and the bleeding pattern this node records.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

3

Blood 1

Mucocutaneous Bleeding VERY_FREQUENT Abnormal bleeding HP:0001892

Show evidence (1 reference)

PMID:20966167 SUPPORT Human Clinical

"Patients with congenital P2Y₁₂ defects display a mild to moderate bleeding diathesis, characterized by mucocutaneous bleedings and excessive post-surgical and post-traumatic blood loss."

Describes mucocutaneous bleeding as the characteristic presentation of affected patients.

Other 2

Incomplete and Reversible ADP-Induced Platelet Aggregation OBLIGATE Impaired platelet aggregation HP:0003540

Show evidence (1 reference)

PMID:20966167 SUPPORT Human Clinical

"Defects of P2Y₁₂ should be suspected when ADP, even at high concentrations (≥ 10 μM), is unable to induce full, irreversible platelet aggregation."

States the finding and its role as the screening criterion, which is why it is curated as obligate in diagnosed patients.

Prolonged Bleeding After Surgery FREQUENT HP:0004846

Show evidence (1 reference)

PMID:20966167 SUPPORT Human Clinical

"excessive post-surgical and post-traumatic blood loss"

Names excessive post-surgical blood loss as a characterizing feature.

🧬

Genetic Associations

1

P2RY12

Gene: P2RY12 hgnc:18124 relationship_type: CAUSATIVE

Show evidence (2 references)

PMID:15852220 SUPPORT Human Clinical

"The fourth patient had an allele with a frame shift mutation and a normal allele, which could be silenced by an additional, as yet unknown, mutation."

Documents the unresolved second allele described in this gene block.

PMID:15852220 SUPPORT Human Clinical

"The two substitutions are located in TM6 and EL3 of the receptor."

Supports the domain localization of the missense alleles named here.

🔬

Diagnosis

1

Aggregometry Plus Adenylyl Cyclase Inhibition Testing

Screening is by aggregometry - incomplete, reversible aggregation to high ADP - but that pattern alone is not confirmatory. Confirmation requires tests that evaluate the degree of inhibition of adenylyl cyclase by ADP, which interrogate the Gi coupling directly. The practical trap is that P2Y12 antagonist drugs reproduce the laboratory picture exactly, so excluding recent clopidogrel, prasugrel or ticagrelor exposure is part of the diagnosis rather than an afterthought.

Show evidence (1 reference)

PMID:20966167 SUPPORT Human Clinical

"Tests that evaluate the degree of inhibition of adenylyl cyclase by ADP should be used to confirm the diagnosis."

States the confirmatory test on which this diagnostic entry rests.

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Platelet-type bleeding disorder 8:

P2Y12 Antagonist Therapy (Acquired Phenocopy)

Overlapping Features Clopidogrel, prasugrel and ticagrelor block the same receptor, so a treated patient has an acquired form of this disorder and is laboratory-identical to one who inherited it. This is the single most common cause of the phenotype by a wide margin and must be excluded first. The reverse observation is also informative: roughly a third of clopidogrel-treated patients fail to inhibit P2Y12 adequately, so the drug does not reliably produce the phenocopy either.

Show evidence (1 reference)

PMID:20966167 SUPPORT Human Clinical

"The most important drawback of clopidogrel is its inability to inhibit adequately P2Y₁₂-dependent platelet function in approximately one-third of patients who are therefore not protected from major cardiovascular events."

Supports the variable-response observation that qualifies the drug phenocopy in this differential.

P2Y1 and P2X1 Receptor Defects

Overlapping Features Platelets carry two other P2 receptors. P2Y1 is Gq-coupled and drives shape change and the initial reversible aggregation wave; P2X1 is the ATP receptor. A defect in either produces a different aggregation signature - notably, loss of P2Y1 removes the shape change that is preserved here.

Show evidence (2 references)

PMID:15852220 SUPPORT Human Clinical

"Platelets possess three P2 receptors: two (P2Y (1) and P2Y (12)) are receptors for adenosine diphosphate (ADP), and one (P2X1) is a receptor for adenosine triphosphate (ATP)."

Establishes the other P2 receptors that form this differential.

PMID:15852220 SUPPORT Human Clinical

"The P2Y (1) receptor, which is coupled to Gq and phospholipase C-beta, is responsible for mobilization of ionized calcium from internal stores and mediates the ADP-induced platelet shape change and initial wave of rapidly reversible aggregation."

Supports the P2Y1 functional description used to distinguish it here.

Dense-Granule Storage Pool Disease

Overlapping Features Dense granules are the platelet's own store of ADP, so a storage pool defect degrades the same amplification loop from the ligand side rather than the receptor side and gives a similar defective second wave of aggregation. Separated by electron microscopy and dense-granule content assays.

Show evidence (1 reference)

PMID:16722529 SUPPORT Human Clinical

"Defects in the second wave of aggregation to ADP or in the response to collagen can imply storage pool disease and an absence of the secretory stores of ADP in dense granules."

States the overlapping aggregation abnormality that makes this a genuine differential.

{ }

Source YAML

click to show

name: Platelet-type bleeding disorder 8
creation_date: "2026-08-24T00:00:00Z"
category: Mendelian
parents:
- Inherited Platelet Disorder
- Bleeding Disorder
disease_term:
  preferred_term: platelet-type bleeding disorder 8
  term:
    id: MONDO:0012354
    label: platelet-type bleeding disorder 8
synonyms:
- BDPLT8
- P2Y12 defect
- ADP platelet receptor P2Y12 defect
- bleeding disorder due to P2RY12 defect
- congenital P2Y12 deficiency
description: >-
  Platelet-type bleeding disorder 8 is a rare inherited platelet function
  disorder caused by variants in P2RY12, the gene for the Gi-coupled platelet
  receptor for ADP. It is the inherited counterpart of the most widely
  prescribed class of antiplatelet drug in the world: clopidogrel, prasugrel and
  ticagrelor all work by blocking exactly the receptor these patients are born
  without, so the disorder is in effect congenital, permanent P2Y12 inhibition,
  and its mild-to-moderate mucocutaneous bleeding phenotype is a direct
  read-out of what that class of drugs does.

  Mechanistically the disorder isolates one half of the platelet's ADP response.
  Platelets carry two ADP receptors: P2Y1, which is Gq-coupled and drives shape
  change and the initial, rapidly reversible wave of aggregation, and P2Y12,
  which is Gi-coupled and negatively regulates adenylyl cyclase, and which
  produces the sustained, progressive aggregation that is not preceded by shape
  change. Both are needed for a full response, so losing P2Y12 alone leaves a
  characteristic signature - ADP, even at high concentrations, produces
  aggregation that is incomplete and reversible instead of full and irreversible.
  P2Y12 also potentiates secretion induced by several other agonists, which is
  why the functional consequence extends beyond ADP responses alone.
pathophysiology:
- name: Loss of Function in P2RY12
  role: trigger
  biological_scale: MOLECULAR
  conforms_to: "primary_hemostatic_plug_failure#Loss of a Platelet Primary-Hemostatic Component"
  description: >-
    Variants in P2RY12 cause the disorder by two distinct routes, both
    documented. In the severe-deficiency families the alleles are frameshifts
    with premature truncation of the protein, so no receptor reaches the
    surface. In at least one compound heterozygote the receptor is expressed and
    trafficked normally but is dysfunctional: p.Arg256Gln in transmembrane helix
    6 and p.Arg265Trp in extracellular loop 3 both reach the cell surface in
    transfected cells and both fail to transduce properly, which identifies that
    region as structurally and functionally critical. A quantitative assay of
    receptor expression would therefore miss the second class entirely.
  genetic_context:
    variant_origin: GERMLINE
    functional_impact_category: LOSS_OF_FUNCTION
  cell_types:
  - preferred_term: platelet
    term:
      id: CL:0000233
      label: platelet
  evidence:
  - reference: PMID:15852220
    reference_title: The P2 receptors and congenital platelet function defects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sequence analysis of the P2Y (12) locus of three of these patients revealed homozygous mutations that produced a frame shift mutation and premature truncation of the protein."
    explanation: >-
      Documents the null allele class in the originally described
      severe-deficiency patients.
  - reference: PMID:15852220
    reference_title: The P2 receptors and congenital platelet function defects.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Neither mutation blocked the ability of the P2Y (12) receptor to translocate to the CHO cell surface."
    explanation: >-
      Establishes the dysfunctional-but-expressed allele class, which is why
      this node distinguishes the two routes.
  downstream:
  - target: Loss of Gi-Coupled ADP Signalling
    causal_link_type: DIRECT
    description: >-
      Whether absent or non-functional, the receptor no longer transduces the
      ADP signal.
- name: Loss of Gi-Coupled ADP Signalling
  role: central_effector
  biological_scale: MOLECULAR
  description: >-
    The rate-limiting lesion. P2Y12 is negatively coupled to adenylyl cyclase
    through Gi, and the functional test that confirms the diagnosis is exactly
    this step: in cells expressing wild-type receptor, ADP strongly inhibits the
    forskolin-induced rise in cyclic AMP across the full concentration range,
    whereas the mutant receptors are only partially inhibitory. Because cyclic
    AMP restrains platelet activation, failure to lower it leaves the platelet
    partially braked at the moment it should be committing to aggregation.
  cell_types:
  - preferred_term: platelet
    term:
      id: CL:0000233
      label: platelet
  molecular_functions:
  - preferred_term: P2Y12 ADP receptor activity
    term:
      id: GO:0001621
      label: G protein-coupled ADP receptor activity
    modifier: LOSS_OF_FUNCTION
  biological_processes:
  - preferred_term: adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway
    term:
      id: GO:0007193
      label: adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:15852220
    reference_title: The P2 receptors and congenital platelet function defects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The other ADP receptor, P2Y (12), is negatively coupled to adenylyl cyclase through Gi and mediates a progressive and sustained ADP-induced aggregation not preceded by shape change."
    explanation: >-
      States the receptor's coupling and the specific aggregation component it
      mediates, which is what this node records as lost.
  - reference: PMID:15852220
    reference_title: The P2 receptors and congenital platelet function defects.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "ADP at all tested concentrations (0.1 to 10 muM) greatly inhibited the forskolin-induced increase of cyclic adenosine monophosphate (cAMP) in CHO cells transfected with wild-type P2Y (12), whereas CHO cells transfected with either mutant protein were only partially inhibited by ADP."
    explanation: >-
      The heterologous assay establishing the signalling defect at the adenylyl
      cyclase step described here.
  downstream:
  - target: Loss of Sustained Aggregation and Agonist-Induced Secretion Potentiation
    causal_link_type: DIRECT
    description: >-
      The Gi arm is what sustains aggregation and potentiates secretion.
- name: Loss of Sustained Aggregation and Agonist-Induced Secretion Potentiation
  role: effector
  biological_scale: CELLULAR
  conforms_to: "primary_hemostatic_plug_failure#Impaired Platelet Activation, Granule Secretion, and Integrin Inside-Out Signalling"
  description: >-
    The functional consequence has two parts, and the second is easy to
    overlook. The obvious one is that the sustained, irreversible phase of ADP
    aggregation is lost while the P2Y1-dependent shape change and initial
    reversible wave remain, so aggregation to ADP is incomplete and reverses
    even at high agonist concentrations - the diagnostic signature. The less
    obvious one is that P2Y12 also potentiates secretion induced by several
    other agonists, so the defect degrades the amplification loop generally
    rather than only the response to ADP.
  cell_types:
  - preferred_term: platelet
    term:
      id: CL:0000233
      label: platelet
  biological_processes:
  - preferred_term: platelet aggregation
    term:
      id: GO:0070527
      label: platelet aggregation
    modifier: DECREASED
  - preferred_term: platelet degranulation
    term:
      id: GO:0002576
      label: platelet degranulation
    modifier: DECREASED
  evidence:
  - reference: PMID:15852220
    reference_title: The P2 receptors and congenital platelet function defects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition, this receptor plays an important role in the potentiation of platelet secretion induced by several platelet agonists. The combined action of P2Y (1) and P2Y (12) is necessary for the full platelet aggregation response to ADP."
    explanation: >-
      Supports both halves of this node - the secretion-potentiation role and
      the requirement for both receptors for a full ADP response.
  - reference: PMID:20966167
    reference_title: "The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Defects of P2Y₁₂ should be suspected when ADP, even at high concentrations (≥ 10 μM), is unable to induce full, irreversible platelet aggregation."
    explanation: >-
      States the diagnostic aggregation signature that this node's first half
      describes.
  downstream:
  - target: Failure of Primary Hemostatic Plug Formation
    causal_link_type: DIRECT
    description: >-
      Loss of sustained aggregation and secretory amplification leaves the plug
      unstable.
- name: Failure of Primary Hemostatic Plug Formation
  role: effector
  biological_scale: TISSUE
  conforms_to: "primary_hemostatic_plug_failure#Failure of Primary Hemostatic Plug Formation"
  description: >-
    A partial rather than a total failure, which is why the bleeding is milder
    than in the receptor and integrin disorders: adhesion, shape change, the
    initial aggregation wave and the integrin itself are all intact, and what is
    lost is the amplification that consolidates the plug. The clearest evidence
    that this step matters haemostatically is pharmacological - blocking the
    same receptor in healthy people is potently antithrombotic and does increase
    major bleeding.
  biological_processes:
  - preferred_term: primary hemostasis
    term:
      id: GO:0007599
      label: hemostasis
    modifier: DECREASED
  evidence:
  - reference: PMID:20966167
    reference_title: "The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Drugs that inhibit P2Y₁₂ are potent antithrombotic drugs, attesting the central role played by P2Y₁₂ in platelet thrombus formation."
    explanation: >-
      Pharmacological evidence that this receptor's contribution to platelet
      thrombus formation is haemostatically consequential.
  downstream:
  - target: Mild to Moderate Mucocutaneous Bleeding Diathesis
    causal_link_type: DIRECT
    description: Failure of platelet-dependent primary hemostasis.
- name: Mild to Moderate Mucocutaneous Bleeding Diathesis
  role: consequence
  biological_scale: ORGANISM
  conforms_to: "primary_hemostatic_plug_failure#Mucocutaneous Bleeding Diathesis"
  description: >-
    Mucocutaneous bleeding with excessive post-surgical and post-traumatic blood
    loss - the same site pattern as the rest of the family but at the mild end
    of its severity range, so the disorder is characteristically unmasked by a
    haemostatic challenge rather than presenting spontaneously.
  biological_processes:
  - preferred_term: primary hemostasis
    term:
      id: GO:0007599
      label: hemostasis
    modifier: DECREASED
  evidence:
  - reference: PMID:20966167
    reference_title: "The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with congenital P2Y₁₂ defects display a mild to moderate bleeding diathesis, characterized by mucocutaneous bleedings and excessive post-surgical and post-traumatic blood loss."
    explanation: >-
      States the severity band and the bleeding pattern this node records.
phenotypes:
- category: Hematologic
  name: Incomplete and Reversible ADP-Induced Platelet Aggregation
  description: >-
    The diagnostic signature: even at ADP concentrations of 10 micromolar or
    above, aggregation is incomplete and reverses, because the P2Y1-dependent
    first wave occurs without the P2Y12-dependent sustained phase.
  phenotype_term:
    preferred_term: Impaired platelet aggregation
    term:
      id: HP:0003540
      label: Impaired platelet aggregation
  frequency: OBLIGATE
  evidence:
  - reference: PMID:20966167
    reference_title: "The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Defects of P2Y₁₂ should be suspected when ADP, even at high concentrations (≥ 10 μM), is unable to induce full, irreversible platelet aggregation."
    explanation: >-
      States the finding and its role as the screening criterion, which is why
      it is curated as obligate in diagnosed patients.
- category: Hematologic
  name: Mucocutaneous Bleeding
  phenotype_term:
    preferred_term: Abnormal bleeding
    term:
      id: HP:0001892
      label: Abnormal bleeding
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:20966167
    reference_title: "The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with congenital P2Y₁₂ defects display a mild to moderate bleeding diathesis, characterized by mucocutaneous bleedings and excessive post-surgical and post-traumatic blood loss."
    explanation: >-
      Describes mucocutaneous bleeding as the characteristic presentation of
      affected patients.
- category: Hematologic
  name: Prolonged Bleeding After Surgery
  phenotype_term:
    preferred_term: Prolonged bleeding after surgery
    term:
      id: HP:0004846
      label: Prolonged bleeding after surgery
  frequency: FREQUENT
  evidence:
  - reference: PMID:20966167
    reference_title: "The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "excessive post-surgical and post-traumatic blood loss"
    explanation: >-
      Names excessive post-surgical blood loss as a characterizing feature.
genetic:
- name: P2RY12
  gene_term:
    preferred_term: P2RY12
    term:
      id: hgnc:18124
      label: P2RY12
  relationship_type: CAUSATIVE
  notes: >-
    Encodes the Gi-coupled platelet ADP receptor P2Y12. Two allele classes are
    reported: frameshift/truncating variants abolishing the receptor, and
    missense variants (p.Arg256Gln in TM6, p.Arg265Trp in EL3) that permit
    normal surface expression but impair signalling. One originally described
    patient carried a frameshift allele together with an apparently normal
    allele that appeared to be silenced by a second, unidentified variant - a
    reminder that a single identified allele does not exclude the diagnosis in a
    patient with the functional phenotype.
  evidence:
  - reference: PMID:15852220
    reference_title: The P2 receptors and congenital platelet function defects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The fourth patient had an allele with a frame shift mutation and a normal allele, which could be silenced by an additional, as yet unknown, mutation."
    explanation: >-
      Documents the unresolved second allele described in this gene block.
  - reference: PMID:15852220
    reference_title: The P2 receptors and congenital platelet function defects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The two substitutions are located in TM6 and EL3 of the receptor."
    explanation: >-
      Supports the domain localization of the missense alleles named here.
inheritance:
- name: Autosomal Recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Every genetically resolved patient in the cached literature is biallelic:
    three with homozygous frameshift variants causing premature truncation, and
    one compound heterozygote carrying p.Arg256Gln and p.Arg265Trp. A fourth
    patient carried one frameshift allele together with an apparently normal
    allele presumed silenced by a second, unidentified variant - consistent with
    recessive inheritance and an undetected second hit rather than with dominant
    disease, though it is explicitly unresolved in the source. Curated as
    autosomal recessive on that basis. Heterozygous carrier phenotype is not
    characterized in the cached sources, and a dominant-negative P2RY12 allele,
    though proposed in the wider literature, is not evidenced by anything cited
    here - so no dominant mode is asserted, and adding one would need its own
    citation and verified snippet.
  evidence:
  - reference: PMID:15852220
    reference_title: The P2 receptors and congenital platelet function defects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sequence analysis of the P2Y (12) locus of three of these patients revealed homozygous mutations that produced a frame shift mutation and premature truncation of the protein."
    explanation: >-
      Establishes homozygous loss-of-function genotypes in the originally
      described severe-deficiency patients, the basis for the recessive
      assignment.
  - reference: PMID:15852220
    reference_title: The P2 receptors and congenital platelet function defects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The fourth patient had an allele with a frame shift mutation and a normal allele, which could be silenced by an additional, as yet unknown, mutation."
    explanation: >-
      PARTIAL - this patient's second allele was never identified, so the case
      is consistent with but does not independently establish recessive
      inheritance. Recorded because the ambiguity is a real caveat for
      diagnostic sequencing, not because it supports the assignment.
diagnosis:
- name: Aggregometry Plus Adenylyl Cyclase Inhibition Testing
  description: >-
    Screening is by aggregometry - incomplete, reversible aggregation to high
    ADP - but that pattern alone is not confirmatory. Confirmation requires
    tests that evaluate the degree of inhibition of adenylyl cyclase by ADP,
    which interrogate the Gi coupling directly. The practical trap is that
    P2Y12 antagonist drugs reproduce the laboratory picture exactly, so
    excluding recent clopidogrel, prasugrel or ticagrelor exposure is part of
    the diagnosis rather than an afterthought.
  evidence:
  - reference: PMID:20966167
    reference_title: "The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tests that evaluate the degree of inhibition of adenylyl cyclase by ADP should be used to confirm the diagnosis."
    explanation: >-
      States the confirmatory test on which this diagnostic entry rests.
differential_diagnoses:
- name: P2Y12 Antagonist Therapy (Acquired Phenocopy)
  description: >-
    Clopidogrel, prasugrel and ticagrelor block the same receptor, so a treated
    patient has an acquired form of this disorder and is laboratory-identical to
    one who inherited it. This is the single most common cause of the phenotype
    by a wide margin and must be excluded first. The reverse observation is also
    informative: roughly a third of clopidogrel-treated patients fail to inhibit
    P2Y12 adequately, so the drug does not reliably produce the phenocopy either.
  evidence:
  - reference: PMID:20966167
    reference_title: "The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most important drawback of clopidogrel is its inability to inhibit adequately P2Y₁₂-dependent platelet function in approximately one-third of patients who are therefore not protected from major cardiovascular events."
    explanation: >-
      Supports the variable-response observation that qualifies the drug
      phenocopy in this differential.
- name: P2Y1 and P2X1 Receptor Defects
  description: >-
    Platelets carry two other P2 receptors. P2Y1 is Gq-coupled and drives shape
    change and the initial reversible aggregation wave; P2X1 is the ATP
    receptor. A defect in either produces a different aggregation signature -
    notably, loss of P2Y1 removes the shape change that is preserved here.
  evidence:
  - reference: PMID:15852220
    reference_title: The P2 receptors and congenital platelet function defects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Platelets possess three P2 receptors: two (P2Y (1) and P2Y (12)) are receptors for adenosine diphosphate (ADP), and one (P2X1) is a receptor for adenosine triphosphate (ATP)."
    explanation: >-
      Establishes the other P2 receptors that form this differential.
  - reference: PMID:15852220
    reference_title: The P2 receptors and congenital platelet function defects.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The P2Y (1) receptor, which is coupled to Gq and phospholipase C-beta, is responsible for mobilization of ionized calcium from internal stores and mediates the ADP-induced platelet shape change and initial wave of rapidly reversible aggregation."
    explanation: >-
      Supports the P2Y1 functional description used to distinguish it here.
- name: Dense-Granule Storage Pool Disease
  description: >-
    Dense granules are the platelet's own store of ADP, so a storage pool defect
    degrades the same amplification loop from the ligand side rather than the
    receptor side and gives a similar defective second wave of aggregation.
    Separated by electron microscopy and dense-granule content assays.
  evidence:
  - reference: PMID:16722529
    reference_title: Glanzmann thrombasthenia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Defects in the second wave of aggregation to ADP or in the response to collagen can imply storage pool disease and an absence of the secretory stores of ADP in dense granules."
    explanation: >-
      States the overlapping aggregation abnormality that makes this a genuine
      differential.
discussions:
- discussion_id: gap_congenital_vs_pharmacological_p2y12_loss
  kind: KNOWLEDGE_GAP
  prompt: >-
    Why is lifelong congenital P2Y12 loss only mildly to moderately
    haemorrhagic when acute pharmacological P2Y12 blockade measurably increases
    major bleeding?
  attaches_to:
  - pathophysiology#Failure of Primary Hemostatic Plug Formation
  - pathophysiology#Mild to Moderate Mucocutaneous Bleeding Diathesis
  rationale: >-
    The same receptor is lost in both cases, yet the clinical weight differs.
    Patients with congenital defects are described as mildly to moderately
    affected, while the newer antagonists, which inhibit P2Y12 effectively in
    most patients, increase the incidence of major bleeding. Several
    explanations are possible and are not distinguished by the available
    evidence: lifelong developmental compensation absent in an acutely treated
    patient; the fact that treated patients are older, comorbid and usually also
    taking aspirin; ascertainment bias, since mildly affected congenital cases
    are the ones that come to attention; or a genuinely more complete blockade
    by drug than by the reported hypomorphic alleles. The question is not
    academic - it determines whether these patients can be counselled using the
    much larger evidence base from antiplatelet trials, which would otherwise be
    the obvious source of guidance for a disorder with only a handful of
    reported cases.
  proposed_experiments:
  - experiment_id: exp_p2y12_congenital_vs_treated_matched_comparison
    name: Matched comparison of residual P2Y12 function and bleeding phenotype
    description: >-
      Quantify residual ADP-induced adenylyl cyclase inhibition in congenital
      P2Y12-defect patients and in ticagrelor-treated volunteers, and pair each
      with a standardized bleeding-assessment tool score. If congenital patients
      retain more residual signalling than fully inhibited treated subjects, the
      difference is one of degree; if they do not, the explanation lies in
      compensation or comorbidity rather than in the receptor.
  evidence:
  - reference: PMID:20966167
    reference_title: "The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although they increase the incidence of major bleedings, the net clinical benefit is in favor of the new P2Y₁₂ inhibitors."
    explanation: >-
      Establishes the drug-side half of the discrepancy - effective blockade
      does increase major bleeding - against which the mild congenital phenotype
      stands to be explained.
notes: >-
  Conformance: this entry conforms to `primary_hemostatic_plug_failure` through
  the SIGNALLING/SECRETION arm - `#Impaired Platelet Activation, Granule
  Secretion, and Integrin Inside-Out Signalling` - which the module names as the
  arm for the agonist-receptor defects (P2Y12, thromboxane A2 receptor, GPVI).
  It does not conform to the aggregation arm: alphaIIbbeta3 is normal and the
  aggregation abnormality is a downstream read-out, exactly the inference the
  module's guidance on that arm warns against.

  The drug relationship is the point of this entry. The disorder is the
  congenital form of what clopidogrel, prasugrel and ticagrelor do
  pharmacologically, which makes it unusually well characterized at the
  mechanistic level for something with only a handful of reported patients - but
  it also means most of the human evidence about P2Y12 blockade comes from
  treated cardiovascular patients rather than from these families. Where a claim
  in this entry rests on the drug literature rather than on the congenital
  patients, it is stated as such (the `Failure of Primary Hemostatic Plug
  Formation` node's evidence, and the acquired-phenocopy differential), and the
  unresolved discrepancy between the two is curated as an explicit knowledge
  gap rather than smoothed over.

  No prevalence record is included: the reported literature amounts to a small
  number of patients, with no published denominator.

  Naming: MONDO:0012354 carries the synonym "bleeding disorder due to P2Rx1
  defect, somatic", which is a MONDO synonym-level conflation of a different
  receptor (P2X1) and should not be treated as an alternative name for this
  entry. The synonyms curated here are the P2Y12 ones only. P2X1 and P2Y1
  defects are curated as differential diagnoses instead.

  No `treatments:` block, deliberately - and here the gap has an unusual shape
  worth naming. Enormous human evidence exists about blocking P2Y12, because
  three widely prescribed drugs do exactly that, but it is evidence about
  inducing this phenotype rather than treating it. Nothing in the cache
  addresses management of the congenital defect. The mechanism does imply the
  general approach (antifibrinolytics and platelet transfusion for bleeding
  episodes, and avoidance of P2Y12 antagonists, which would compound a defect
  the patient already has), and the avoidance point is clinically real - but it
  is an inference, so it is stated here rather than curated as an evidenced
  treatment. As with the other conformers, the module's rFVIIa pattern is not
  inherited.

  Curation provenance. This entry was curated by direct review of the cached
  full text and abstracts of the references listed in `references:`, not from a
  deep-research provider artifact, so there is no corresponding file under
  `research/`. Candidate PMIDs were located by PubMed search and each was
  fetched with `just fetch-reference` before use; several initially plausible
  identifiers turned out to be unrelated papers and were discarded rather than
  cited on their titles. Every snippet in this entry is an exact substring of
  the cached reference text.
references:
- reference: PMID:20966167
  title: "The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects."
- reference: PMID:15852220
  title: "The P2 receptors and congenital platelet function defects."
- reference: PMID:21781244
  title: "Advances in our understanding of the molecular basis of disorders of platelet function."

📚

References & Deep Research

References

3

PMID:20966167

The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.

No top-level findings curated for this source.

PMID:15852220

The P2 receptors and congenital platelet function defects.

No top-level findings curated for this source.

PMID:21781244

Advances in our understanding of the molecular basis of disorders of platelet function.

No top-level findings curated for this source.

Platelet-type bleeding disorder 8

Ask OpenScientist

OpenScientist Report

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Diagnosis

Differential Diagnoses

Source YAML

References & Deep Research

References